Literature DB >> 7822270

Alternatively spliced juxtamembrane domain of a tyrosine kinase receptor is a multifunctional regulatory site. Deletion alters cellular tyrosine phosphorylation pattern and facilitates binding of phosphatidylinositol-3-OH kinase to the hepatocyte growth factor receptor.

C C Lee1, K M Yamada.   

Abstract

The hepatocyte growth factor (HGF) receptor is a tyrosine kinase receptor that mediates signal transduction upon ligand stimulation. This receptor is present in mouse tissues as two major isoforms differing by a 47-amino acid segment in the juxtamembrane domain, an alternatively spliced cytoplasmic region adjacent to the transmembrane domain of the receptor. We report here that the juxtamembrane domain of the receptor is involved in the regulation of downstream signal transduction. The two receptor isoforms were transiently expressed in COS-7 cells. Both exogenous receptors underwent autophosphorylation and subsequently stimulated a set of protein tyrosine phosphorylations that were not present in control cells. Comparisons of phosphotyrosine profiles of transfected cell lysates induced by receptor isoforms demonstrated that at least three phosphorylated proteins of approximately 62, approximately 35, and approximately 30 kDa were differentially induced by the receptor isoforms, suggesting that the juxtamembrane domain of a kinase receptor can play a role in selective signal transduction. Furthermore, the p85 subunit of phosphatidylinositol-3-OH kinase (PI3 kinase) co-precipitated with the small isoform of the HGF receptor, and this association was dramatically inhibited by treatment with 12-O-tetradecanoylphorbol-13-acetate. Since removal of the juxtamembrane domain facilitates the binding of p85 to the receptor, it is likely that the juxtamembrane region plays a role in negative regulation of the binding of PI3 kinase to the HGF receptor. Our study establishes novel molecular sequelae of alternative splicing of an intracellular domain of the HGF receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7822270     DOI: 10.1074/jbc.270.2.507

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage.

Authors:  David Tulasne; Julien Deheuninck; Filipe Calheiros Lourenco; Fabienne Lamballe; Zongling Ji; Catherine Leroy; Emilie Puchois; Anice Moumen; Flavio Maina; Patrick Mehlen; Véronique Fafeur
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

2.  Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.

Authors:  J Voortman; T Harada; R P Chang; J K Killian; M Suuriniemi; W I Smith; P S Meltzer; M Lucchi; Y Wang; G Giaccone
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

3.  Single-nucleotide polymorphism rs41736 located in MET was significantly associated with prognosis of small cell lung cancer patients.

Authors:  Xu Cao; Xuan Hong; Xiaoli Jia; Liping Zhang; Gang Chen
Journal:  Med Oncol       Date:  2014-11-22       Impact factor: 3.064

4.  MET∆14 promotes a ligand-dependent, AKT-driven invasive growth.

Authors:  Marina Cerqua; Orsola Botti; Maddalena Arigoni; Noemi Gioelli; Guido Serini; Raffaele Calogero; Carla Boccaccio; Paolo M Comoglio; Dogus M Altintas
Journal:  Life Sci Alliance       Date:  2022-05-30

5.  A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype.

Authors:  C Collesi; M M Santoro; G Gaudino; P M Comoglio
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

6.  Characterization of the enhancing effect of protamine on the proliferative activity of hepatocyte growth factor in rat hepatocytes.

Authors:  Ke-Xin Liu; Yukio Kato; Kunio Matsumoto; Toshikazu Nakamura; Taiichi Kaku; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2009-01-06       Impact factor: 4.200

7.  Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.

Authors:  Mary J Gray; Peter Kannu; Swarkar Sharma; Christine Neyt; Dongping Zhang; Nandina Paria; Philip B Daniel; Heather Whetstone; Hans-Georg Sprenger; Philipp Hammerschmidt; Angela Weng; Lucie Dupuis; Rebekah Jobling; Roberto Mendoza-Londono; Michael Dray; Peiqiang Su; Megan J Wilson; Raj P Kapur; Edward F McCarthy; Benjamin A Alman; Andrew Howard; Gino R Somers; Christian R Marshall; Simon Manners; Adrienne M Flanagan; Karl E Rathjen; Lori A Karol; Haemish Crawford; David M Markie; Jonathan J Rios; Carol A Wise; Stephen P Robertson
Journal:  Am J Hum Genet       Date:  2015-12-03       Impact factor: 11.025

Review 8.  MET meet adaptors: functional and structural implications in downstream signalling mediated by the Met receptor.

Authors:  Victor Martin Bolanos-Garcia
Journal:  Mol Cell Biochem       Date:  2005-08       Impact factor: 3.842

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.